Introduction
Patients with suspected acute myocardial infarction (MI) account for approximately 10% of all emergency department (ED) patients. 1, 2 Those patients with MI are at high risk and require further diagnostic evaluation or invasive treatment. According to the current universal definition type 1 and type 2 MI (T1MI, T2MI) are differentiated based on the pathophysiological background. 3 T1MI is defined by an acute coronary plaque disruption, while T2MI is defined by an imbalance of myocardial oxygen supply and demand. Those patients with T1MI usually require an urgent invasive approach to improve outcome. 4 Patients with T2MI on the other hand reflect a heterogeneous population with various other causes of symptoms, and an early invasive approach might not only be not warranted, but even harmful in those patients. Therefore, differentiation of both MI types represents a clear clinical need. The causes of T2MI include e.g. arrhythmias, cardiogenic shock, coronary spasm, and other causal factors. The prevalence of T2MI has been reported between 2 and 30% of all MI patients. 5 As elevated troponin concentrations are essential for the diagnosis of T1MI as well as T2MI, it is not surprising that troponin measured by mediumsensitivity assays was not able to differentiate between both types. 6 Nevertheless, the clinical characteristics differ as T2MI patients tend to be older, are more often females and have different symptoms compared to T1MI patients. [7] [8] [9] Furthermore, earlier studies reported a poor outcome of T2MI patients with mortality rates of up to 50% after 4 years. [9] [10] [11] [12] The large Swedeheart register identified coronary artery disease (CAD) as an important determinant for T2MI since these were at highest risk for death and had more often cardiovascular comorbidities. 10 Again, this highlights that differentiation of these two subtypes of MI is clinically important, but remains a challenging task for ED physicians or the consulting cardiologists. Therefore, in the present article, we aim to investigate the clinical characteristics and the cardiovascular outcome of patients with T2MI in a large prospective cohort of patients with suspected MI. Furthermore, we aim to differentiate patients with T2 from T1MI patients based on available clinical findings in order to improve decision making for ED physicians.
Methods

Study population
Data from the Biomarkers in Acute Cardiac Care (BACC) study were used for the analyses. An earlier version of this study population has been published before. 13, 14 In the present analyses, we had data of 1641 patients who presented with suspected MI to the ED of the University Heart Center Hamburg. The enrolment took place between 19 July 2013 and 10 April 2016. Patients were not included when the age was below 18 years or the patient was not able or willing to provide written informed consent. Patients with ST-elevation MI (n = 75) and with non-ST-elevation MI type 4 (n = 2) were excluded from the analyses. Sixteen patients were excluded due to missing hs-TnI values. The BACC study was approved by the local Ethics Committee and registered at www.clinicaltrials.gov (NCT02355457). The study design complied with the Declaration of Helsinki.
Study design
All patients with suspected MI were treated according to the current ESC Guidelines, including electrocardiogram (ECG), monitoring, serial measurement of high-sensitivity troponin T (hs-TnT, ElecsysV R , Roche diagnostics) at admission and after 3 h as well as further imaging.
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Depending on the individual results, each patient was discharged or admitted for further treatment. Independently from clinical routine, hsTnI was measured using the Architect immunoassay (Abbott Diagnostics, ARCHITECT i1000SR) at admission, after 1 and 3 h. This assay had a limit of detection at a concentration of 1.9 ng/L and a 10% coefficient of variation at a concentration of 5.2 ng/L. 16 In the general population, the 99th percentile has been reported at 27 ng/L. 17 An ECG was performed immediately after presentation to the ED and directly interpreted by the ED physician. The ECG interpretation and the clinical assessment are described in the Supplementary material online.
Adjudication of myocardial infarction diagnosis
The final diagnosis of each patient was determined by two physicians (J.T.N. and N.A.S.) separately. In cases of disagreement, a third cardiologist (D.W.) reviewed the case. The final diagnosis was based on all available clinical and imaging results, ECG and standard laboratory testing, including hs-TnT and creatinine. Adjudication was performed according to the ESC guidelines at least 30 days after the index admission. 
Statistical analysis
Continuous variables were described as quartiles; categorical variables as absolute numbers and percentages. The Wilcoxon rank-sum (for continuous variables) or the v 2 (for categorical variables) test were employed for between-group comparisons.
Outcome
Survival curves for the non-MI, T1MI, and T2MI patients were produced using the Kaplan-Meier method. Survival curve differences were tested with the log-rank test. Hazard ratios for each adverse event (adjusted for age, sex, and CAD) were estimated using Cox regression.
Score development
The detailed score development is described in the Supplementary material online.
Results
Baseline characteristics
Out of 1548 patients with suspected MI, 188 were diagnosed with T1MI and 99 (34.5% of all MI) with T2MI ( Table 1) . The median age for the overall study population was 65 (25th and 75th percentile 51, 75) years, while patients with T2MI were significantly older than T1MI patients (69 vs. 72 years, P-value = 0.039). Patients with T2MI were more often female (48.5% vs. 28.2%, P-value < 0.001) and more likely to have atrial fibrillation (34.3% vs. 10.6%, P-value < 0.001). Not having a history of CAD (70.7% vs. 48.9%, P-value < 0.001), not presenting with typical radiating chest pain (82.7% vs. 56.1%, P-value < 0.001)
. Figure S1 ). Patients with T2MI underwent angiography in 38.3% (T1MI 86.7%, P-value < 0.001) and none of these patients received PCI. In T2MI patients undergoing angiography, 60.5% had only nonsignificant CAD or microvessel disease, while 10.5% had one-vessel disease, 7.9% two-vessel disease, and 21.1% had three-vessel disease (all non-obstructive, Supplementary material online, Table S1 ). The most common causes of T2MI (covering 74% of all cases) were severe hypertension, arrhythmias, and acute decompensated heart failure. The exact causes of T2MI are displayed in Supplementary material online, Table S2 . When comparing non-MI and T2MI patients, those with T2MI were significantly older (72 vs. 63 years, P-value < 0.001), more often female (36.5 vs. 48.5%, P-value = 0.023), had more often hypertension (65.3 vs. 77.8%, P-value = 0.015), congestive heart failure (13.5 vs. 25.3%, P-value = 0.002), atrial fibrillation (17.2 vs. 34.3%, P-value < 0.001) and worse renal function (estimated glomerular filtration rate 79.6 vs. 62.88 mL/min for 1.73 m 2 , P-value < 0.001) (Supplementary material online, Table S1 ). All serial troponin concentrations were significantly higher for T2MI compared to non-MI patients.
Outcome
The events of death, incident MI, PCI, and cardiac rehospitalization were documented for non-MI, T1MI, and T2MI patients separately ( Figure 1) . The unadjusted 1-year mortality rate was higher for T1MI and T2MI patients compared with non-MI patients (4.1% for the latter vs. 9.4% and 13.8%, respectively), while the difference between T1MI and T2MI was not statistically significant. There were no incident MIs in T2MI patients and only one PCI within the follow-up period. In non-MI patients, the unadjusted rates of incident MI were 0.6% and 3.7% for PCI. Both events were most common in T1MI patients with an unadjusted event rate of 3.9% (MI) and 12.0% (PCI). Adjustment for age, sex, and history of CAD did not change the magnitude and direction of the reported differences in event rates (Supplementary material online, Table S3 ). Cardiac rehospitalization within 1 year after admission occurred in 18.8% of non-MI, 19.3% of T2MI, and 33.8% of T1MI patients (significantly higher for T1MI vs. T2MI in the unadjusted model with P = 0.025, but not significant after adjustment for age, sex and CAD).
The exact cause of death, the duration until death, and the initial maximum cardiac biomarkers of T2MI patients are displayed in Supplementary material online, only two cases of a cardiac origin of death (both heart failure), while most other cases were caused by cancer and respiratory failure.
Score development
In order to distinguish T2MI from T1MI patients, a logistic regression model was developed. The optimal hs-TnI cut-off concentration, derived from an receiver operating characteristic (ROC) curve, was < _ 40.8 ng/L for the 0-h sample, < _ 68 ng/L for 1 h and < _ 330.9 ng/l for 3 h (Supplementary material online, Figure S2 ). Table 2) . This model resulted in an AUC of 0.71, which was superior to each single variable alone ( Figure 3 , Supplementary material online, Table S5 ). The calibration of this model is displayed in Supplementary material online, Figure S3 . These three variables (sex, angina, and troponin) of the multivariable model were transferred to a binary score with one point per variable ( Figure 4 ). Patients with the highest possible score of 3 had a 72% probability of T2MI, while patients with a score of 0 had a 5% probability of T2MI. The diagnostic performance and the ROC curve of the binary score are displayed in Supplementary material online, Figure S4 and Supplementary material online, Table S6 .
Discussion
In a large prospective study, we demonstrate that patients with type 2 myocardial infarction represent a heterogeneous population with high-cardiovascular risk. Furthermore, we were able to identify the most important predictors, which might help physicians to differentiate patients presenting with T2MI or T1MI ( Figure 5 ). 
Type 1 and type 2 myocardial infarction
Patients with suspected MI frequently present to the ED and require an early decision-making to either rule-out, rule-in, or observe. 2 While the rule-out of MI based on high-sensitivity troponin provides a high level of confidence, there is less certainty regarding the rule-in of patients. Patients with symptoms suggestive of MI and dynamic changes of troponin would usually be grouped to rule-in and diagnosed with MI. The physician now should decide if an angiography needs to be performed, either urgently or electively. While this is recommended by current guidelines in most T1MI patients, urgent angiography might not be beneficial for T2MI patients. T2MI patients have heterogeneous causes of symptoms, which included arrhythmias, heart failure and severe hypertension in our study. Therefore, treatment of the underlying pathology is the primary goal of treatment in T2MI. As all patients present with symptoms of MI and have elevated troponin per definition of MI, the clinical differentiation is challenging. Earlier studies utilizing medium-sensitivity troponin were not able to differentiate between T1MI and T2MI based on this biomarker. 6 Using highsensitivity troponin assays, even lowest concentrations can be measured accurately. 19 By utilizing a high-sensitivity troponin I assay, we could document distinct changes of troponin at admission, after 1 and 3 h for T1MI and T2MI patients. As expected, T2MI patients had lower hs-TnI concentrations. Nevertheless, a single cut-off resulted in an AUC of only 0.63. This shows that a single troponin cut-off is not able to differentiate between both entities. Therefore, we aimed to include additional clinical relevant parameters to identify T2MI patients. After multivariable selection, we identified female sex, typical radiating chest pain and a baseline hs-TnI < _ 40.8 ng/L as the most important predictors. These parameters are easily accessible in the ED and can be obtained rapidly after admission. The combination of these parameters to a binary score improved the discrimination to an AUC of 0.71. These findings highlight that the distinction of T1MI and T2MI remains challenging even after this careful selection of diagnostic parameters. However, these identified predictors might help physicians to differentiate T1MI and T2MI patients. What could be the clinical benefit of this differentiation? Patients with T2MI often have coexisting obstructive CAD 10 and invasive angiography might be reasonable at some point in time. However, in our study only 38% of all T2MI patients underwent angiography and none received revascularization at the index admission or in the follow-up period. Therefore, T2MI patients should not undergo invasive strategies within the ED, but as discussed above require treatment of the underlying cause. In summary, we would emphasize the careful clinical evaluation of T2MI patients, which might (but not unalterable) include invasive angiography at some point in time. For T1MI patients, an urgent invasive strategy is clearly recommended. A high score could differentiate these different populations and identify T2MI patients.
Comparison to previous studies
Compared with previous studies, our study design differs significantly: prior studies with focus on T2MI were mostly performed in registers or cohorts with unselected determination of troponin. 10, 20 In the BACC study, we prospectively included only patients with suspected MI. These patients would be addressed in the ED setting in order to decide whether a patient should undergo early invasive diagnostics. This setting is important with regards to the causes of T2MI. Earlier studies included patients with severe infection or anaemia who had dynamic troponin changes. These populations are barely represented in the BACC study, where most causes for T2MI were cardiac related including heart failure, hypertension, and arrhythmias. Earlier studies reported very high-mortality rates for T2MI patients of up to 50% after 4 years. In our present study, we could not validate these high-mortality rates. Again, this might be explained by the preselection of patients with suspected MI. Nevertheless, T2MI patients had a mortality rate that was comparable to T1MI patients. Interestingly, most T2MI patients in our study died from cancer or respiratory failure and barely from cardiac reasons. These findings are in line with prior publications with focus on T2MI. 21 Furthermore, in patients with suspected MI we could recently show, that hs-TnI concentrations between 6 and 27 ng/L were associated with a higher mortality rate, while cardiac causes of death were rare. 22 Taken together, these findings highlight the predictive value of elevated troponin concentrations for future events. Elevated troponin concentrations without dynamic changes can be caused by various conditions including chronic heart failure, chronic kidney disease or stabile CAD. 23 This is labelled as myocardial injury and also associated with poor outcome. 9 The differentiation of T2MI and myocardial injury is challenging and there is substantial overlap for several conditions (e.g. acute and chronic heart failure or stable CAD with borderline stenosis and new onset atrial fibrillation). Therefore, this topic remains a matter of debate [24] [25] [26] and needs to be addressed in future studies and guidelines.
Strengths and limitations
One strength of our study is that we prospectively included patients with suspected MI, who represent a clinically important population. The adjudication of the final diagnosis has been performed carefully and blinded by two physicians, which is another strength. Nevertheless, the exact definition of T2MI is crucial and challenging even after blinded adjudication. Therefore, some cases could have been misclassified. However, during the follow-up period no MI and only one PCI were observed for T2MI patients. This could indicate that no T1MI was falsely classified to be T2MI. Nevertheless, in future studies more detailed imaging results should be investigated for T2MI patients. A second limitation is that our results are specific for highsensitivity troponin I and therefore limited to this assay. Finally, external validation of the developed point score is required in order to show the robustness of the model. Provided is the logistic regression for T2MI as the dependent variable. The predictors were chosen via backward step-down selection (using total residual AIC as the stopping rule). MI, myocardial infarction; T1MI, type 1 myocardial infarction; T2MI, type 2 myocardial infarction; OR, odds ratio; CI, confidence interval. Figure 5 Central illustration of T1MI and T2MI patients. T1M1, type 1 myocardial infarction; T1M2, type 2 myocardial infarction.
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